Antioxidant therapeutics for Schizophrenia

Antioxidants and Redox Signaling

Volumn 15, Issue 7, 2011, Pages 2047-2055

  Reddy, Ravinder ^a,b   Reddy, Rajiv ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CAROTENE; CLOZAPINE; GINKGO BILOBA EXTRACT; GLUTATHIONE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIOCTIC ACID; UBIQUINONE; URIC ACID; ZIPRASIDONE;

AKATHISIA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FREE RADICALS; HUMANS; SCHIZOPHRENIA;

EID: 80051960519     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3571     Document Type: Review

References (56)

1. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, and Angrist B. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 150: 1405-1407, 1993. (Pubitemid 23259578)
2. Akhtar S, Jajor TR, and Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med 39: 124-126, 1993.
3. Al-Chalabi BM, Thanoon IA, and Ahmed FA. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 59: 8-11, 2009.
4. Anonymous. Vitamin E treatment for tardive dyskinesia: Veterans Affairs Cooperative Study 394 Study Group. Arch Gen Psychiatry 56: 836-841, 1999.
5. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, and Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 62: 195-204, 2003. (Pubitemid 36773928)
6. Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, and McGorry PD. Ethyl-eicosapentaenoic acid in firstepisode psychosis: an 1H-MRS study. Neuropsychopharmacology 33: 2467-2473, 2008.
7. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, and Bush AI. Nacetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64: 360-368, 2008.
8. Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I, Jeavons S, Katz F, Anderson-Hunt M, Conus P, Hanna B, Otmar R, Ng F MBBS, Copolov D, and Bush AI. Qualitative methods in early-phase drug trials: data and methods from a trial of N-acetyl cysteine in schizophrenia. J Clin Psychol (in press)
9. Bishnoi M, Chopra K, and Kulkarni SK. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fund Clin Pharmacol 21: 521-529, 2007. (Pubitemid 47404330)
10. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297: 842-857, 2007. (Pubitemid 46333949)
11. Cadet JL and Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 570: 176-185, 1989. (Pubitemid 20103394)
12. Cantuti-Castelvetri I, Shukitt-Hale B, and Joseph JA. Neurobehavioral aspects of antioxidants in aging. Int J Dev Neurosci 18: 367-381, 2000. (Pubitemid 30243068)
13. Cantuti-Castelvetri I, Shukitt-Hale B, and Joseph JA. Neurobehavioral aspects of antioxidants in aging. Int J Dev Neurosci 18: 367-381, 2000. (Pubitemid 30243068)
14. Dabiri LM, Pasta D, Darby JK, and Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 151: 925-926, 1994.
15. Dakhale GN, Khanzode SD, Khanzode SS, and Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 182: 494-498, 2005. (Pubitemid 41464630)
16. Dietrich-Muszalska A and Olas B. Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro. World J Biol Psychiatry 11: 276-281, 2010.
17. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, and Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12: 3721-3728, 2000.
18. Dorevitch A, Kalian M, Shlafman M, and Lerner V. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 41: 114-116, 1997. (Pubitemid 27050652)
19. Dorfman-Etrog P, Hermesh H, Prilipko L, Weizman A, and Munitz H. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study. Eur Neuropsychopharmacol 9: 475-477, 1999. (Pubitemid 30089059)
20. Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, Blum A, Saenz RE, and Wyatt RJ. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 149: 773-777, 1992.
21. Elkashef AM, Ruskin PE, Bacher N, and Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 147: 505-506, 1990. (Pubitemid 20107122)
22. Emsley R, Oosthuizen P, and van Rensburg SJ. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 17: 1081-1091, 2003. (Pubitemid 38021394)
23. Gawryluk JW, Wang JF, Andreazza AC, Shao L, and Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 11:1-8, 2010.
24. Hall ED. Brain attack: acute therapeutic interventions: free radical scavengers and antioxidants. Neurosurg Clin North Am 8: 195-206, 1997. (Pubitemid 27224210)
25. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298-300, 1956.
26. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, and Oepen G. One hundred years of schizophrenia: a metaanalysis of the outcome literature. Am J Psychiatry 151: 1409-1416, 1994. (Pubitemid 24301683)
27. Kim E, Park DW, Choi SH, Kim JJ, and Cho HS. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia. J Clin Psychopharmacol 28: 138-146, 2008. (Pubitemid 351417118)
28. Kim J, Lee HJ, and Lee KW. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem 112: 1415-1430, 2010.
29. Lam LC, Chiu HF, and Hung SF. Vitamin E in the treatment of tardive dyskinesia: a replication study. J Nerv Ment Dis 182: 113-114, 1994. (Pubitemid 24134992)
30. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuenod M, Buclin T, and Do KQ. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33: 2187-2199, 2008. (Pubitemid 351992093)
31. Lohr JB, Cadet JL, Lohr MA, Jeste DV, and Wyatt RJ. Alphatocopherol in tardive dyskinesia. Lancet 1: 913-914, 1987.
32. Lohr JB and Caligiuri MP. A double-blind placebocontrolled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 57: 167-173, 1996. (Pubitemid 26123363)
33. Magliaro BC and Saldanha CJ. Clozapine protects PC-12 cells from death due to oxidative stress induced by hydrogen peroxide via a cell-type specific mechanism involving inhibition of extracellular signal-regulated kinase phosphorylation. Brain Res 1283: 14-24, 2009.
34. Mahadik SP and Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 55: 45-54, 1996. (Pubitemid 26321117)
35. Mahadik SP, Pillai A, Joshi S, and Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 18: 119-131, 2006. (Pubitemid 43791675)
36. Marra MV and Boyar AP. Position of the American Dietetic Association: nutrient supplementation. J Am Diet Assoc 109: 2073-2085, 2009.
37. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Takanashi J, Matsuda T, Shimizu E, Ikehira H, Iyo M, and Hashimoto K. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 3: e1944, 2008.
38. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142: 37-46, 2005.
39. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 suppl 1: 20-27, 2007.
40. Padurariu M, Ciobica A, Dobrin I, and Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 479: 317-320, 2010.
41. Parikh V, Khan MM, and Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 37: 43-51, 2003. (Pubitemid 35449770)
42. Peet M, Laugharne J, Rangarajan N, and Reynolds GP. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 8: 151-153, 1993. (Pubitemid 23294920)
43. Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 45: 19-25, 2008.
44. Reddy R and Keshavan M. Schizophrenia: A Practical Primer. Abingdon: Informa Healthcare, 2006.
45. Reddy R and Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 55: 33-43, 1996. (Pubitemid 26321116)
46. Reddy R, Keshavan MS, and Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 30: 901-911, 2004. (Pubitemid 40469524)
47. Salmasi FB, Jazayeri M, Ghaeli P, Hashemian F, Akhondzadeh S, Raisi F, Hosseini SH, Setareh MJ, and Khavidaki SD. Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine. J Clin Psychopharmacol 29: 182-183, 2009.
48. Shriqui CL, Bradwejn J, Annable L, and Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 149: 391-393, 1992.
49. Singh V, Singh SP, and Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol 13: 257-271, 2010.
50. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, and Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an openlabel pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31: 1493-1499, 2007. (Pubitemid 47302571)
51. Soares KV and McGrath JJ. Vitamin E for neurolepticinduced tardive dyskinesia. Cochrane Database Syst Rev CD000209, 2001.
52. Su HM. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J Nutr Biochem 21: 364-373, 2010.
53. Tandon R, Nasrallah HA, and Keshavan MS. Schizophrenia, "Just the Facts" 5: treatment and prevention: past, present, and future. Schizophr Res (in press).
54. Uyama O, Matsuyama T, Michishita H, Nakamura H, and Sugita M. Protective effects of human recombinant superoxide dismutase on transient ischemic injury of CA1 neurons in gerbils. Stroke 23: 75-81, 1992.
55. Yao JK, Leonard S, and Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 22: 83-93, 2006. (Pubitemid 41831607)
56. Yao JK and Keshavan MS. Antioxidants, redox signaling, and pathophysiology of schizophrenia: an integrative view. Antioxid Redox Signal 15: 2011-2035, 2011.